• MIRI.DIH

  Led · Series B · Jul 2024

  Miridih provides a SaaS-based design platform called MiriCanvas and a print-on-demand (POD) service named BizHows. MiriCanvas serves 13 million users, positioning the company strongly in the domestic market. Led by CEO Kang Changseok and based in Seoul, Miridih plans to use new funding for talent acquisition and global marketing to accelerate international expansion. The company has shown rapid revenue growth, reporting KRW 14.7 billion in 2020, KRW 19.3 billion in 2021, KRW 33.1 billion in 2022, and KRW 60.7 billion in 2023. In 2023 Miridih recorded an operating profit of KRW 7.7 billion. The company announced plans to select an IPO underwriter in the second half of 2024 and begin formal IPO preparations.

• ExoCoBio

  Participated · Series C · Aug 2020

  ExoCoBio develops exosome-based regenerative aesthetic products and brands. Founded in 2017 and led by CEO Byong Cho, the company has launched ASCE+™, EXOMAGE™, and CELLTWEET™. Those brands target skin rejuvenation, skin immune-modulation, and scalp rejuvenation. The company raised $9.3m in Series C and pre-IPO funding and has cumulatively raised about $56.3m since founding. ExoCoBio has established a strategic alliance with BENEV Company Inc., an FDA-registered medical aesthetic manufacturer in Orange County, California, to support U.S. market activities. The financing is positioned to support continued commercialization of its exosome product lines and near-term growth initiatives. ExoCoBio Inc. is a pharmaceutical R&D and cosmeceutical company developing exosome-based products. The company produces exosome pharmaceuticals and has launched cosmeceutical brands and products such as EXOMAGE™, Celltweet™ and ASCE+™. ExoCoBio works with exosomes—nano-vesicles secreted by cells that contain physiologically active substances and can stimulate cellular or tissue regeneration, with applications in skin and hair. The company plans to use recent funding to set up GMP-compliant exosome manufacturing facilities, hire talent, and secure additional commercialization opportunities in the cosmetics industry. Financially, ExoCoBio raised approximately $26.7M in a Series B and has raised about $46M cumulatively, including an $11M Series A in April 2017. The company was established in January 2017 and is led by CEO Byong Cho.

• Hummingbird Bioscience

  Led · Series B · Dec 2019

  Hummingbird Bioscience discovers and engineers precision therapeutics using a proprietary Rational Antibody Discovery platform to target optimal yet elusive epitopes. The company is advancing a pipeline of first- and best-in-class therapies in oncology and autoimmunity, including clinical-stage assets. Lead programs include HMBD-001, a HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti‑VISTA neutralizing antibody for advanced solid tumors. The company is also progressing HMBD-009, a BCMA‑TACI dual‑specific T cell engager, as part of its next‑generation pipeline. Hummingbird collaborates with global partners in academia and industry to advance its programs. Piers Ingram is CEO and co-founder. Hummingbird Bioscience is a biotherapeutics company developing antibody-based treatments for cancer and other diseases. The company has published data on two oncology antibodies and expects to submit regulatory filings to start Phase 1 studies in the second half of this year. It said the new funding will be used to accelerate those therapies into clinical trials and to expand research and development for its early-stage pipeline. Hummingbird has offices in Singapore, Houston and South San Francisco and strategic collaborations with Cancer Research UK and Amgen. It was previously awarded a product development grant from the Cancer Prevention and Research Institute of Texas. Financially, the company has now raised $65 million in total, with the Series B reaching $25 million after the recent extension. Hummingbird Bioscience is a biotherapeutics company developing precision antibody therapeutics using a proprietary rational antibody discovery platform and systems biology expertise. It is building a broad pipeline of first- and best-in-class drug candidates across multiple indications, including HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA) for cancer. The company raised US$19M in a Series B and intends to use the funds to discover new disease targets, expand its antibody pipeline, and accelerate co-discovery projects under a multi-target collaboration with Amgen. HMBD-001 and HMBD-002 are expected to enter first-in-human clinical trials following regulatory submissions in the second half of 2020. The Series B was co-led by Mirae Asset Venture Investment and GNTech Venture Capital, with participation from existing investors Heritas Capital and Seeds Capital and new investors including Delian Capital, Mirae Asset Capital, DAValue-GiltEdge, HB Investment, Wooshin Venture Investment, and Kiwoom Investment-Shinhan Capital. Led by CEO and co-founder Dr. Piers Ingram, the company has strategic collaborations with Cancer Research UK and Amgen and is based in Singapore, Houston (Texas) and South San Francisco (California).

• ImmunoMet Therapeutics

  Participated · Series B · Mar 2017

  ImmunoMet Therapeutics is a clinical-stage biotechnology company developing metabolism-targeted anti-fibrotic and anti-cancer therapies, with lead candidate IM156, a protein complex 1 (PC1) inhibitor. IM156 targets the OXPHOS pathway to decrease the supply of energy and anabolic precursors required to drive fibrotic disease and tumor growth, and is solely owned by the company. The U.S. FDA has cleared an IND for IM156 in idiopathic pulmonary fibrosis (IPF) and granted it Orphan Drug Designation. ImmunoMet plans to initiate a single-site U.S. Phase 1 study in 32 healthy volunteers in Q1 2021 to characterize safety, tolerability, pharmacokinetics, and effects, with data intended to inform a Phase 2 trial in IPF. The company recently completed a Korean Phase 1 trial of IM156 in oncology patients and reported good tolerability at doses previously tested in humans. Financially, ImmunoMet has raised $31M to date and has closed $7.0M in new financing to help fund the Phase 1 program. ImmunoMet Therapeutics focuses on targeting cellular metabolism to develop novel anti-cancer and anti-fibrotic therapies. Its lead candidate, IM156, is a potent Protein Complex 1 (PC1) inhibitor that targets the oxidative phosphorylation (OXPHOS) pathway and is solely owned by the company. IM156 completed a Phase 1 study in healthy volunteers with good tolerability and the company has established target engagement. ImmunoMet also owns a large library of biguanides that it may develop internally or with partners for multiple indications. The company plans a food effect study in Q1 2022 to optimize IM156 dosing and is preparing for Phase 2 oncology trials, aiming to be in the clinic in multiple oncology indications by Q4 2022. Founded in 2015 and headquartered in JLABS @ TMC in Houston, ImmunoMet is advancing clinical and development activities supported by recent financing. ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies. Its lead program, IM156, is an OXPHOS inhibitor expected to enter a Phase 1 clinical trial in the second quarter of 2017. The company is also developing an immuno-oncology program, IM188, in combination with immunotherapies including an anti-PD1; IM188 is in late-stage lead optimization and has demonstrated tumor regression in a renal cancer model. ImmunoMet intends to use the new funding to advance the Phase 1 study for IM156 and the preclinical studies of its immuno-oncology program focused on inhibiting immune suppressor cells. The company is a spinoff of HanAll and is headquartered at JLABS in Houston. Leadership includes founder, Chairman and CEO Dr. Sung-wuk Kim and COO Benjamin R. Cowen. ImmunoMet Therapeutics is a development-stage biotechnology spinoff of HanAll Biopharma led by CEO Sung-wuk Kim. The company has developed novel technology intended to disrupt cancer cell growth and enhance anti-cancer immunity, with potential application across a broad range of difficult-to-treat cancers. Its lead compound, IM156, for the treatment of glioblastoma was expected to enter Phase 1 clinical development in the second half of 2016. The company raised $5.2M in a Series A funding round and intends to use the proceeds to advance research and clinical development programs. ImmunoMet also plans to establish its worldwide headquarters in Houston, TX and to fund general corporate purposes. The company is focused on moving its lead program into clinical testing and supporting broader R&D efforts.

• Eutilex

  Participated · Series A · Dec 2016

  Eutilex focuses on developing anti-tumor T cell and antibody therapeutics, with an emphasis on adoptive T cell therapy. The company completed a 21 billion KRW (US$18.9M) Series A to fund its immuno-oncology programs. It has raised 30.5 billion KRW (US$27.7M) since its founding in 2015. Proceeds will be used to accelerate development and commercialization of programs and to advance its lead candidate, 4-1BB CTL, into Phase 2 clinical studies. Eutilex also plans to expand R&D capabilities by building a new Good Manufacturing Practice (GMP) facility in Seoul. Other pipeline candidates include monoclonal antibodies EU-101, EU-102 and EU-103; the company is led by founder and CEO Byoung S. Kwon, Ph.D.

No current team members are available.